Table 2.
Correlation of WWOX protein expression with classical prognostic factors such as histological grade, tumour stage, tumour size, multiplicity, and with predictive factors related to recurrent and progressive disease
| WWOX protein expression level
|
Total | P-value | |||
|---|---|---|---|---|---|
| Low | Moderate | High | |||
|
| |||||
| Grade | |||||
| PUNLMP | 0 | 1 (12.5%) | 7 (87.5%) | 8 (100%) | |
|
| |||||
| LGPUC | 3 (12.5%) | 9 (37.5%) | 12 (50%) | 24 (100%) | |
|
| |||||
| HGPUC | 19 (29.7%) | 14 (21.9%) | 31 (48.4%) | 64 (100%) | 0.012* |
|
| |||||
| UCSM | 4 (80%) | 1 (20%) | 0 (0%) | 5 (100%) | 0.001 |
|
| |||||
| Stage | |||||
| pTa | 6 (12.8%) | 13 (27.7%) | 28 (59.6%) | 47 (100%) | |
|
| |||||
| pT1 | 7 (30.4%) | 5 (21.7%) | 11 (47.8%) | 23 (100%) | 0.002 |
|
| |||||
| pT2–4 | 13 (42%) | 7 (22.6%) | 11 (35.5%) | 31 (100%) | |
|
| |||||
| Size, mm | |||||
| <10 | 2 (25%) | 0 (0%) | 6 (75%) | 8 (100%) | |
|
| |||||
| 10–30 | 8 (17.4%) | 14 (30.4%) | 24 (52.2%) | 46 (100%) | |
|
| |||||
| >30 | 16 (34%) | 11 (23.4%) | 20 (42.6%) | 47 (100%) | 0.04 |
|
| |||||
| Multiplicity | |||||
| No | 13 (24.5%) | 10 (18.9%) | 31 (57.4%) | 54 (100%) | |
|
| |||||
| Yes | 13 (27.1%) | 15 (31.6%) | 19 (40.4%) | 47 (100%) | 0.11 |
|
| |||||
| Recurrence | |||||
| No | 17 (25%) | 17 (25%) | 34 (50%) | 68 (100%) | |
|
| |||||
| Yes | 9 (27.3%) | 8 (24.2%) | 16 (48.5%) | 33 (100%) | 0.416 |
|
| |||||
| Progression | |||||
| No | 15 (19.7%) | 21 (27.6%) | 40 (52.6%) | 76 (100%) | |
|
| |||||
| Yes | 11 (44%) | 4 (16%) | 10 (40%) | 25 (100%) | 0.028 |
|
| |||||
| N+ | |||||
| No | 16 (22.2%) | 18 (25%) | 39 (53.4%) | 73 (100%) | |
|
| |||||
| Yes | 10 (35.7%) | 7 (25%) | 11 (39.3%) | 28 (100%) | 0.067 |
|
| |||||
| M+ | |||||
| No | 23 (24.5%) | 25 (26.6%) | 46 (48.9%) | 94 (100%) | |
|
| |||||
| Yes | 3 (42.9%) | 0 (0%) | 4 (57.1%) | 7 (100%) | 0.379 |
|
| |||||
| Treatment | |||||
| TUR alone | 7 (18%) | 11 (28.2%) | 21 (53.8%) | 39 (100%) | |
|
| |||||
| TUR + AT | 8 (19%) | 11 (26.2%) | 23 (54.8%) | 42 (100%) | |
|
| |||||
| Cystectomy | 11 (55%) | 3 (15%) | 6 (30%) | 20 (100%) | 0.024 |
|
| |||||
| Total | 18 (17.8%) | 33 (32.7%) | 50 (45.5%) | 101 (100%) | |
PUNLMP, Papillary urothelial neoplasms of low malignant potential; LGPUC, low-grade papillary urothelial carcinomas; HGPUC, high-grade papillary urothelial carcinomas; UCSM, urothelial carcinomas with squamous metaplasia; L+, lymph node metastases; M+, systemic metastases; P-value, PCA and Kendall’s correlation coefficient; AT, adjuvant therapy.
When HGPUC plus UCSM are grouped into the same category of high-grade urothelial carcinomas, then the P-value is 0.012 when compared with PUNLMP, although no significant differences with LGPUC were observed.